受注:045-509-1970 |
技術サポート:[email protected] 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
Synonyms | Koloxo, Loxoprofene, Loxoprofeno | Storage (From the date of receipt) |
3 years -20°C powder 1 years -80°C in solvent |
|
化学式 | C15H18O3 |
|||
分子量 | 246.30 | CAS No. | 68767-14-6 | |
Solubility (25°C)* | 体外 | DMSO | 49 mg/mL (198.94 mM) | |
Ethanol | 49 mg/mL (198.94 mM) | |||
Water | Insoluble | |||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
製品説明 | Loxoprofen (Koloxo, Loxoprofene, Loxoprofeno) is a non-steroidal anti-inflammatory drug in the propionic acid derivatives group. |
---|---|
in vitro | Loxoprofen sodium(LOX) does not affect the proliferation and viability of LLC cells in vitro. HUVECs treated with LOX results in the inhibition of the tubular formation. Treatment with 50 mg/ml LOX reveals a 33% decline in in vitro angiogenesis, compared with vehicle-treated HUVECs. This inhibition is presumably due to inhibition of VEGF activity[1]. |
in vivo | Loxoprofen sodium (LOX), inhibits in vivo growth of implanted Lewis lung carcinoma (LLC). Intratumoral vessel density in LOX-treated mice is significantly lower than that of mice without treatment. Intratumoral expressions of vascular endothelial growth factor (VEGF) mRNA are attenuated by the LOX treatment. LOX suppresses both intratumoral and systemic VEGF protein in LLC-implanted mice. LOX also inhibits tubular formation of primary cultured human umbilical vein endothelial cells, presumably due to the inhibition of VEGF. In patients with advanced non-small cell lung cancer, LOX medication (120 mg/day) for a week significantly decreases the plasma VEGF level[1]. |
細胞アッセイ | 細胞株 | LLC cells |
---|---|---|
濃度 | 50 μg/ml | |
反応時間 | 0-6 days | |
実験の流れ | To determine the proliferation of LLC cells with or without Loxoprofen, 2×104 cells are seeded into 100-mm dishes containing 10 ml culture medium supplemented with 50 μg/ml Loxoprofen or vehicle on day 0. On days 2, 3, 4 and 6, the cells are trypsinized and counted. |
|
動物実験 | 動物モデル | C57BL/6 and BDF1 mice |
投薬量 | 60 μg/ml | |
投与方法 | via drinking water |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。